Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review

<div>Top—CT and PET-CT images April 2012 before alisertib showing 2.1 cm R hilar mass (a) with SUV 4.8 (b) and R para-tracheal soft tissue prominence with fibrotic changes in previously irradiated field (c) with SUV 5.2 (d). Bottom—CT and PET-CT images December 2012 after 10 cycles of alisertib showing resolution of R hilar mass (a, b) and unchanged R para-tracheal cicatricial changes (c) with maximum SUV of 2.3 (d).</div>

Case Reports in Oncological Medicine

fig3

Figure 3

Figure 3: Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review 

Figure 3 | Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review 